Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NACDS WILL BEGIN TWO-YEAR LEADERSHIP TRANSITION: BOLGER SETS RETIREMENT

Executive Summary

NACDS WILL BEGIN TWO-YEAR LEADERSHIP TRANSITION: BOLGER SETS RETIREMENT for 1987, the Natl. Assn. of Chain Drug Stores announced in a Sept. 5 press release. NACDS said that current President Robert Bolger, 63, head of the assn. for over 18 years, "has announced his intention to retire from NACDS during 1987." NACDS has appointed a selection cmte. with the responsibility for finding a successor to Bolger. NACDS is planning an orderly succession with time for overlap before Bolger departs. The assn. announcement states that the selection cmte. "has expressed its desire to bring the future NACDS President on board in August 1986." If the selection cmte. is able to meet the August deadline, Bolger could have over a year to help his successor acclimate to the position. Bolger's contract is scheduled to run out Dec. 31, 1987. Recently, both the Natl. Whsle. Druggists' Assn. (NWDA) and the American Pharmaceutical Assn. (APhA) have adopted similar phased-in succession plans for incoming leadership. The NWDA currently has former Drug Whslrs. Assn. (DWA) head Charles Trefrey in the assn. management group as heir-designate to succeed William Ford as president when he retires at the end of 1986. APhA was in the midst of a four year transition period begun in early 1982 when then-president William Apple died unexpectedly in December 1983. Named to the NACDS selection cmte. are the assn. Vice Chairman Alex Grass (Rite Aid), assn. board directors Sidney Dworkin (Revco), Sheldon Fantle (Peoples), Stewart Turley (Jack Eckerd), C.R. Walgreen III (Walgreen), Gerald Wolken (SupeRx), and Bolger. NACDS is likely to enlist an outside executive search firm to round up candidates for the job. Bolger characterized the best candidate as a "generalist. . .who can wear a lot of hats" while being a "quick learner that can get involved very quickly in complicated issues such as Medicaid reimbursement reform." Bolger has been with NACDS for 23 years, including 18 years at the assn.'s helm. His previous experience before NACDS included eleven years with SmithKline & French. Bolger joined NACDS in 1962 as asst. to exec VP James Merritt. Bolger later moved to the position of director of trade relations at the assn. On March 1, 1967, he took over as interim exec VP of NACDS following Merritt's departure to the Toilet Goods Assn. (the forerunner of the Cosmetic, Toiletry, and Fragrance Assn.) Bolger dropped "interim" from his title after an NACDS' exec cmte. meeting in May 1967. When he retires in 1987, he will have headed the assn. staff for 20 years. A native of Philadelphia, Bolger earned a BS in economics from Villanova University. He later attended graduate school at Northwestern University and the University of Pennsylvania, and received a Certificate of Internatl. Economics from the University of Geneva.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel